Compliance with minimum standards was met for the proportion of patients with HER2-negative invasive carcinoma (T > 1 cm or node-positive) treated with chemotherapy who did not receive adjuvant trastuzumab (96.3% [95% CI 93–99%]) and for the proportion of patients with ER-negative invasive carcinoma (T > 1 cm or node-positive) who received adjuvant chemotherapy (65.6% [95% CI 49–82]). Here, ERBB2 is linked to invasive carcinoma.